Monitor the Federal Circuit's Moderna 1498 appeal decision, which could unlock a $1.3B contingent payment. Watch for next steps on AB-101 clinical development after FDA lift. Track progress of international LNP lawsuits against Pfizer/BioNTech for potential future damages or settlements.
Drugs in focus
ABUS drug pipeline →AB-101
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1a/1b
- Time to market
- AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
- Next catalyst
- None dated
What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $3.82entry
- T+1 · 6d ago +1.57%α +0.25% · $3.88
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Arbutus reported Q3 2026 net income of $59.1M ($0.30/share), driven by a $67.3M dividend from Genevant, versus a $7.7M net loss in Q3 2025. Operating revenue was $0.3M, down from $0.5M a year ago. The company completed a $230M tender offer in October, repurchasing 23% of shares. The FDA lifted the clinical hold on AB-101, and new LNP patent lawsuits were filed in Japan and Canada against Pfizer/BioNTech. The Moderna 1498 appeal oral argument was held on Nov 5, with a decision pending.
Key Financial Metrics
Key Facts
- Q3 2026 net income of $59.1M vs net loss of $7.7M in Q3 2025
- Total revenue of $0.3M, down from $0.5M in Q3 2025
- Cash and marketable securities of $337.5M as of Sept 30, 2026
- Completed $230M modified Dutch auction tender offer in Oct 2026, repurchasing 46M shares (23% of outstanding)
- Received $67.3M cash dividend from Genevant in Sept 2026
- FDA lifted clinical hold on AB-101 (oral PD-L1 inhibitor) IND
- Filed new LNP patent lawsuits in Japan and amended Canadian lawsuit against Pfizer/BioNTech
- Moderna 1498 appeal oral argument held Nov 5, 2026, decision pending
- Operating loss of $10.5M in Q3 2026 vs $8.7M in Q3 2025
- R&D expenses decreased to $2.6M from $5.8M; G&A increased to $8.0M from $3.0M due to one-time executive bonuses
Financial Impact
Net income of $59.1M primarily from $67.3M Genevant dividend; operating loss of $10.5M; $230M returned to shareholders via tender offer
Risk Factors
- Operating revenue remains minimal ($0.3M) with no near-term product sales
- Operating loss widened to $10.5M from $8.7M due to higher G&A expenses
- Moderna 1498 appeal outcome is uncertain; contingent $1.3B payment may not materialize
- LNP litigation against Pfizer/BioNTech is ongoing with no guaranteed outcome
- Clinical-stage pipeline with no approved products; AB-101 development plans not yet defined
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-007311 |
| Document: f8k_111026.htm | 0001171843-26-007311 |
| Document: 0001171843-26-007311-index-headers.html | 0001171843-26-007311 |
| Document: 0001171843-26-007311-index.html | 0001171843-26-007311 |
| Document: 0001171843-26-007311.txt | 0001171843-26-007311 |
| 8-K Data (Synthetic) | 0001171843-26-007311 |
Track record
25 reports on ABUS
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +11.55% at T+20 after the Aug 12, 2026 report. 6 of 12 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $4.04 Now $4.04 −0.00% settles Feb 16
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $4.07 Now $4.04 −0.74% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $4.03 Now $4.04 +0.25% settles Feb 10
- Nov 10, 20266d ago 8-K Neutral 5/10 Viewing Entry $3.82 Now $4.04 +5.76% settles Feb 8
- Nov 10, 20266d ago Press Release Neutral 4/10 No price data
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $3.66 Now $4.04 −10.53% settles Feb 4
- Oct 22, 202625d ago 8-K Bullish 6/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $4.21 Now $4.04 −4.04% settles Jan 20
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $4.18 Now $4.04 −3.35% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers